Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Irbesartan Formulations in Healthy Chinese Subjects
NCT05786339Phase 1Completed
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Nov 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of irbesartan in hypertension (HTN) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Curve from time 0 to last measurable concentration at 48 hours and 1 more. Started Nov 2018; status: completed.
02
Drugs
irbesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05786339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786339.